ArticleBlood2025

A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up.

Sherilyn A Tuazon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.